Sept 1 (Reuters) – The U.S. drug regulator has asked Pfizer (PFE.N), Eli Lilly & Co (LLY.N) and AbbVie (ABBV.N) to include information about the risks of serious conditions and death from the use of their drugs that belong to a class of treatments known as JAK inhibitors.
The warnings on Wednesday stem from the U.S. Food and Drug Administration’s review of Pfizer’s arthritis drug Xeljanz after initial results from a February trial showed an increased risk of serious heart-related problems and cancer with the drug.
AbbVie shares closed down 7%, while Pfizer and Eli Lilly were slightly lower.
